ES2132841T3 - Compuestos de naftilo, intermedios, composiciones y procedimientos. - Google Patents

Compuestos de naftilo, intermedios, composiciones y procedimientos.

Info

Publication number
ES2132841T3
ES2132841T3 ES96300877T ES96300877T ES2132841T3 ES 2132841 T3 ES2132841 T3 ES 2132841T3 ES 96300877 T ES96300877 T ES 96300877T ES 96300877 T ES96300877 T ES 96300877T ES 2132841 T3 ES2132841 T3 ES 2132841T3
Authority
ES
Spain
Prior art keywords
sub
sup
compounds
formula
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96300877T
Other languages
English (en)
Inventor
Alan David Palkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2132841T3 publication Critical patent/ES2132841T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/257—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings
    • C07C43/295—Ethers having an ether-oxygen atom bound to carbon atoms both belonging to six-membered aromatic rings containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
    • C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA COMPUESTOS FARMACEUTICAMENTE ACTIVOS DE LA FORMULA (I) DONDE R{SUP,1} ES -H, -OH, -O(C{SUB,1}-C{SUB,4}ALQUIL), OCOC{SUB,6}H{SUB,5}, -OCO(C{SUB,1}-C{SUB,6}ALQUIL), O OSO{SUB,2}(C{SUB,2}-C{SUB,6}ALQUIL); R{SUP,2} ES -H, -OH, -O(C{SUB,1}-C{SUB,4}ALQUIL), OCOC{SUB,6}H{SUB,5}, -OCO(C{SUB,1}-C{SUB,6}ALQUIL), OSO{SUB,2}(C{SUB,2}-C{SUB,6}ALQUIL), O HALO R{SUP,3} ES 1-PIPERIDINILO, 1-PIRROLIDINILO, METIL-1-PIRRODINILO, DIMETIL-1-PIRROLIDINO, 4-MORFOLINO, DIMETILAMINO, DIETILAMINO, DIISOPROPILAMINO, O 1-HEXAMETILENOIMINO; Y N ES 2 O 3; Y O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS. TAMBIEN SE PROPORCIONAN COMPUESTOS DE LA FORMULA (II): DONDE R{SUP,1A} ES -H O -OR{SUP,5} EN EL QUE R{SUP,5} ES UN GRUPO PROTECTOR DE HIDROXI. R{SUP,2A} ES -H, HALO O -OR{SUP,6} EN EL QUE R{SUP,6} ES UN GRUPO PROTECTOR DE HIDROXI; Y R{SUP,4} ES -OH O -CHO; O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS. SE PROPORCIONAN ADEMAS COMPOSICIONES FARMACEUTICAS DE LA FORMULA (I), Y METODOS PARA UTILIZAR LOS COMPUESTOS DE LA FORMULA PARA, ENTRE OTRAS COSAS, ALIVIAR LOS SINTOMAS DEL SINDROME POSMENOPAUSICO Y EL CANCER HORMONALMENTE DEPENDIENTE, PARTICULARMENTE EL CANCER DE MAMA.
ES96300877T 1995-02-28 1996-02-09 Compuestos de naftilo, intermedios, composiciones y procedimientos. Expired - Lifetime ES2132841T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/395,950 US5998401A (en) 1995-02-28 1995-02-28 Naphthyl compounds, intermediates, compositions, and methods

Publications (1)

Publication Number Publication Date
ES2132841T3 true ES2132841T3 (es) 1999-08-16

Family

ID=23565221

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96300877T Expired - Lifetime ES2132841T3 (es) 1995-02-28 1996-02-09 Compuestos de naftilo, intermedios, composiciones y procedimientos.

Country Status (32)

Country Link
US (5) US5998401A (es)
EP (1) EP0729951B1 (es)
JP (1) JPH08268881A (es)
KR (1) KR960030938A (es)
CN (2) CN1053886C (es)
AR (2) AR001036A1 (es)
AT (1) ATE180776T1 (es)
AU (1) AU694837B2 (es)
BR (1) BR9600821A (es)
CA (1) CA2170337A1 (es)
CO (1) CO4700421A1 (es)
CY (1) CY2178B1 (es)
CZ (1) CZ288213B6 (es)
DE (1) DE69602638T2 (es)
DK (1) DK0729951T3 (es)
ES (1) ES2132841T3 (es)
FI (1) FI115524B (es)
GR (1) GR3030407T3 (es)
IL (1) IL117168A (es)
IN (1) IN182138B (es)
MX (1) MX9600743A (es)
MY (1) MY113232A (es)
NO (1) NO305833B1 (es)
NZ (1) NZ286072A (es)
PE (1) PE28497A1 (es)
PL (1) PL183578B1 (es)
RU (1) RU2167849C2 (es)
SG (1) SG55098A1 (es)
TR (1) TR199600126A1 (es)
TW (1) TW349946B (es)
YU (1) YU11496A (es)
ZA (1) ZA961291B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) * 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5856340A (en) 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
ID19392A (id) * 1996-08-29 1998-07-09 Lilly Co Eli Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan
CA2213814A1 (en) * 1996-08-29 1998-02-28 Henry Uhlman Bryant Naphthalene compounds, intermediates, formulations, and methods
SI0826679T1 (en) * 1996-08-29 2002-04-30 Eli Lilly And Company Naphthyl compounds and compositions
CA2214929A1 (en) * 1996-09-26 1998-03-26 Charles Willis Lugar, Iii Naphthofluorene compounds, intermediates, compositions and methods
CA2214931A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Tetrahydrobenzo-a-fluorene compounds and method of use
CA2214935A1 (en) * 1996-09-26 1998-03-26 Henry Uhlman Bryant Benzofluorene compounds, intermediates, compositions, and methods
CA2217810A1 (en) * 1996-10-10 1998-04-10 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
PA8444901A1 (es) * 1997-01-28 2000-05-24 Hoffmann La Roche Derivados de 5-aroilnaftaleno como agentes anti-inflamatorios
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
WO1999007377A1 (en) 1997-08-07 1999-02-18 Eli Lilly And Company 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
IL145839A0 (en) 1999-04-16 2002-07-25 Astrazeneca Ab ESTROGEN RECEPTOR-β LIGANDS
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
KR100370597B1 (ko) * 2000-06-22 2003-02-05 박정일 산형매립초로부터 분리한 신규한 나프탈렌계 화합물 및이를 유효성분으로 하는 약학적 조성물
WO2002044119A2 (en) * 2000-11-28 2002-06-06 Eli Lilly And Company Synthesis of 2-aryl-1-naphthol derivatives via a tandem palladium catalyzed arylation and dehydrogenation
JP2004531559A (ja) * 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
WO2002094788A1 (en) 2001-05-22 2002-11-28 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
US9315539B2 (en) * 2002-10-01 2016-04-19 Yale University 11 beta-short chain substituted estradiol analogs and their use in the treatment of menopausal symptoms and estrogen sensitive cancer
BRPI0407690A (pt) 2003-02-25 2006-03-01 Lilly Co Eli composto, e, métodos para tratar endometriose e para tratar leiomioma uterino
CN100348192C (zh) * 2003-02-25 2007-11-14 伊莱利利公司 晶状的非溶剂化1－(4－(2－哌啶基乙氧基)苯氧基)－2－(4－甲磺酰基苯基)－6－羟基萘盐酸化物
US20040253319A1 (en) * 2003-06-11 2004-12-16 Shrirang Netke Pharmaceutical compositions and method for alleviating side-effects of estrogen replacement therapy
WO2005051893A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1687265A2 (en) * 2003-11-20 2006-08-09 Eli Lilly And Company Vitamin d receptor modulators
JP4909086B2 (ja) 2004-01-22 2012-04-04 イーライ リリー アンド カンパニー 血管運動性症候の治療のための選択的エストロゲン受容体モジュレーター
CN1910167B (zh) * 2004-01-22 2011-08-10 伊莱利利公司 用于治疗血管舒缩症状的选择性雌激素受体调节剂
DE602005017577D1 (de) 2004-01-22 2009-12-24 Lilly Co Eli Selektive östrogen-rezeptor-modulatoren
RU2352555C2 (ru) * 2004-06-22 2009-04-20 Смитклайн Бичем Корпорейшн ХИМИЧЕСКИЕ СОЕДИНЕНИЯ, СОДЕРЖАЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ИХ ПРИМЕНЕНИЕ (ВАРИАНТЫ) И СПОСОБ СВЯЗЫВАНИЯ ERα И ERβ-ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ
KR101319675B1 (ko) * 2008-09-29 2013-10-22 일라이 릴리 앤드 캄파니 골관절염의 치료를 위한 선택적 에스트로겐 수용체 조절자
MX2012014579A (es) 2010-06-16 2013-05-22 Endorech Inc Procedimientos de tratamiento o pevencion de enfermedades relacionadas con estrogenos.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) * 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) * 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3862232A (en) * 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3313853A (en) * 1963-10-16 1967-04-11 Upjohn Co 2-(tertiaryaminoalkoxyphenyl)-3, 4-dihydronaphthalenes and 2-(tertiaryaminoalkoxyphenyl) -3, 4- dihydro -1(2h)-naphthalenones
US3293263A (en) * 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3320271A (en) * 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
DE1300575B (de) * 1965-05-21 1969-08-07 Bristol Myers Co Benzo[b]thiophene
US3394125A (en) * 1965-10-23 1968-07-23 Bristol Myers Co 2-phenyl-3-tertiary-aminoalkoxy phenyl-and corresponding tertiaryaminoalkyl thio benzfurans substituted in the benzo nucleus with an alkoxy or tertiaryamino alkoxy or alkylthio group
US3483293A (en) * 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) * 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US3862323A (en) 1971-09-20 1975-01-21 Betz Laboratories Dioxide slime control composition and its use
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4400543A (en) * 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
DE3121175A1 (de) * 1981-05-27 1982-12-16 Klinge Pharma GmbH, 8000 München Erythro-1,2,3-triphenyl-1-pentanon-derivate sowie verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8311678D0 (en) * 1983-04-28 1983-06-02 Ici Plc Phenol derivatives
GB8705174D0 (en) * 1987-03-05 1987-04-08 Ici Plc Heterocyclic compounds
US5013761A (en) * 1988-06-03 1991-05-07 Eli Lilly And Company Serotonin antagonists
FR2665444B1 (fr) 1990-08-06 1992-11-27 Sanofi Sa Derives d'amino-benzofuranne, benzothiophene ou indole, leur procede de preparation ainsi que les compositions les contenant.
US5254568A (en) * 1990-08-09 1993-10-19 Council Of Scientific & Industrial Research Benzopyrans as antiestrogenic agents
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
US5147880A (en) * 1991-07-22 1992-09-15 Eli Lilly And Company Benzo[a]fluorene compounds
JPH07502268A (ja) * 1991-11-27 1995-03-09 ノボ　ノルディスク　アクティーゼルスカブ 化学化合物、それらの製法および使用
US5424334A (en) 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5998401A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
MX9600743A (es) 1997-02-28
YU11496A (sh) 1999-03-04
CN1152683C (zh) 2004-06-09
US5998401A (en) 1999-12-07
BR9600821A (pt) 1997-12-23
TR199600126A1 (tr) 1996-10-21
DE69602638D1 (de) 1999-07-08
RU2167849C2 (ru) 2001-05-27
IL117168A (en) 2001-11-25
TW349946B (en) 1999-01-11
CA2170337A1 (en) 1996-08-29
NO960772L (no) 1996-08-29
US6268361B1 (en) 2001-07-31
US6355632B1 (en) 2002-03-12
CZ58196A3 (en) 1996-09-11
CN1261534A (zh) 2000-08-02
FI960889A0 (fi) 1996-02-26
SG55098A1 (en) 1998-12-21
ATE180776T1 (de) 1999-06-15
JPH08268881A (ja) 1996-10-15
IL117168A0 (en) 1996-06-18
PE28497A1 (es) 1997-08-27
AU694837B2 (en) 1998-07-30
CY2178B1 (en) 2002-08-23
CN1137525A (zh) 1996-12-11
EP0729951B1 (en) 1999-06-02
CO4700421A1 (es) 1998-12-29
EP0729951A1 (en) 1996-09-04
MY113232A (en) 2001-12-31
DK0729951T3 (da) 1999-06-23
ZA961291B (en) 1997-08-19
NZ286072A (en) 1996-10-28
US5574190A (en) 1996-11-12
AR001036A1 (es) 1997-08-27
NO305833B1 (no) 1999-08-02
FI115524B (fi) 2005-05-31
DE69602638T2 (de) 1999-10-21
CZ288213B6 (en) 2001-05-16
GR3030407T3 (en) 1999-09-30
US5567712A (en) 1996-10-22
IN182138B (es) 1999-01-09
FI960889A (fi) 1996-08-29
PL312829A1 (en) 1996-09-02
AR002964A1 (es) 1998-05-27
PL183578B1 (pl) 2002-06-28
CN1053886C (zh) 2000-06-28
NO960772D0 (no) 1996-02-26
AU4573296A (en) 1996-09-05
KR960030938A (ko) 1996-09-17

Similar Documents

Publication Publication Date Title
ES2132841T3 (es) Compuestos de naftilo, intermedios, composiciones y procedimientos.
ES2163587T3 (es) Compuestos de benzotiofeno, productos intermedios, composiciones y procedimientos.
KR830006174A (ko) 기관지 항경련성 화합물 제조방법
ES2039278T3 (es) Procedimiento para preparar inhibidores de 5-alfa-reductasa de esteroides.
KR920700209A (ko) 치환된 벤조[5,6]사이클로헵타피리딘의 헤테로사이클릭 n-옥사이드 유도체, 조성물 및 용도
AR017195A1 (es) Derivados de benzodioxano, benzofurano o benzopirano, proceso para su preparacion, composicion farmaceutica que los contiene y proceso para su preparacion.
UY28674A1 (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
ES2173154T3 (es) Compuestos de naftilo, intermedios, procedimientos y composiciones de los mismos.
ATE205184T1 (de) Metalloproteinase inhibitoren
PH31601A (en) Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxyenase inhibitors.
ES2036562T3 (es) Un procedimiento para produccion de un derivado de pirrolidinamida.
ES2179996T3 (es) Cefalosporinas de vinil-pirrolidinona con sustituyentes basicos.
SE7603085L (sv) Diazepinderivat
ES2142763B1 (es) Derivados de 5'-desoxicitidina.
SE316473B (es)
KR910016660A (ko) 스쿠알렌 에폭시다제 억제제로서의 스쿠알렌의 디-및 테트라-플루오르 유사체
AR006991A1 (es) Analogo hidrosoluble de 20(s)- camptotecina, una composicion farmaceutica que los contiene, una medicina para el tratamiento del cancer, leucemia oestados relacionados con el hiv, el uso de dichos compuestos y un procedimiento para su preparacion
AR012157A1 (es) Derivados de piridina, composiciones farmaceuticas que los contienen y procedimiento para la preparacion de dichos derivados.
ECSP034494A (es) Inhibidores novedosos de la farnesil proteino trasferasa como agentes antitumorales
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
AR041720A1 (es) Derivados de n- benzodioxolilo, n- benzodioxanilo y n- benzodioxepinilarilcarboxamida que pueden usarse para el tratamiento de dislipidemia, y composiciones farmaceuticas que los contienen
PT97032A (pt) Processo para a preparacao de derivado do acido (benzidriloxi-etilpiperidil)-alifatico utilizaveis como agente anti-histaminicos
AR125490A1 (es) Terapias de combinación que utilizan un anticuerpo anti-bcma conjugado a fármaco (adc) en combinación con un inhibidor de gamma secretasa (gsi)
ES2142545T3 (es) Minimizacion de la perdida osea por combinaciones de antiestrogenos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 729951

Country of ref document: ES